banner
bextetobias.bsky.social
Tobias Bexte
@bextetobias.bsky.social
38 followers 28 following 2 posts
Physician | Scientist | Immunotherapies | NK cells | Gene-editing Frankfurt am Main https://www.linkedin.com/in/tobias-bexte-76643b124/
www.linkedin.com
Posts Media Videos Starter Packs
bextetobias.bsky.social
Tobias Bexte @bextetobias.bsky.social · 21d
🚨 Paper alert!
"Next-gen multiplex-edited CAR-NK cells: more edits, more power?" @jitc @bmj.com
With @dlwagner.bsky.social we discuss Wang et al.’s landmark paper on multiplex base-edited non-viral CAR-NK cells. Promising efficiency but safety challenges! jitc.bmj.com/content/13/9...
Next-generation multiplex-edited CAR-NK cells: more edits, more power?
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ c...
jitc.bmj.com
1 5
bextetobias.bsky.social
Tobias Bexte @bextetobias.bsky.social · Jul 8
🥳 #PaperAlert 🚨
Huge congrats to my lab-bestie Lisa Marie Reindl!! 💪🎉 So proud of you!😎🌟
EGFR-tarheting CAR NKcells in combination with radiotherapy showed significant tumor reduction ex vivo and in vivo in hard-to-treat solid tumors of rhabdomyosarcoma!
jitc.bmj.com/content/13/7... @bmj.com
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy
Background: Rhabdomyosarcoma (RMS) is the most common type of soft-tissue sarcoma in children, and it remains a challenging cancer with poor outcomes in high-risk and metastatic patients. This study r...
jitc.bmj.com
3